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Abstract
Atypical teratoid/rhabdoid tumor (AT/RT) is an extremely malignant neoplasm in the central nervous system (CNS) which
occurs in infancy and childhood. Recent studies suggested that CD133 could be considered a marker for brain cancer stem-
like cells (CSCs). However, the role of CD133 in AT/RT has never been investigated. Herein we report the isolation of CD133-
positive cells (CD133
+), found to have the potential to differentiate into three germ layer tissues, from tissues of nine AT/RT
patients. The migration/invasion/malignancy and radioresistant capabilities of CD133
+ were significantly augmented when
compared to CD133
2. The clinical data showed that the amount of CD133
+ in AT/RTs correlated positively with the degree
of resistance to radiation therapy. Using cDNA microarray analysis, the genotoxic–response profiles of CD133
+ and CD133
2
irradiated with 10 Gy ionizing radiation (IR) were analyzed 0.5, 2, 6, 12 and 24 h post-IR. We then validated these microarray
data and showed increased phosphorylation after IR of p-ATM, p-RAD17, and p-CHX2 as well as increased expression of BCL-
2 protein in CD133
+ compared to CD133
2. Furthermore, we found that CD133
+ can effectively resist IR with cisplatin- and/or
TRAIL-induced apoptosis. Immunohistochemical analysis confirmed the up-regulated expression of p-ATM and BCL-2
proteins in IR-treated CD133
+ xenotransgrafts in SCID mice but not in IR-treated CD133
2. Importantly, the effect of IR in
CD133
+ transplanted mice can be significantly improved by a combination of BCL-2 siRNA with debromohymenialdisine, an
inhibitor of checkpoint kinases. In sum, this is the first report indicating that CD133
+ AT/RT cells demonstrate the
characteristics of CSCs. The IR-resistant and anti-apoptotic properties in CD133
+ may reflect the clinical refractory
malignancy of AT/RTs and thus the activated p-ATM pathway and BCL-2 expression in CD133
+ could be possible targets to
improve future treatment of deadly diseases like AT/RT.
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Introduction
Atypical teratoid/rhabdoid tumor (AT/RT), primary to the
central nervous system (CNS), is a rare, aggressive, and highly
malignant tumor which commonly occurs in patients under 3
years of age and is often fatal within 1 year after diagnosis [1–4].
Though usually described as extremely rare, AT/RT comprises
up to 25% of primitive CNS tumors in infants [5]. In the past, the
majority of AT/RTs were misclassified as primitive neuroecto-
dermal tumors (PNET)/medulloblastoma (MB) at supratentorial
sites because of the similarities in radiological and histological
features of these two tumors [6,7]. Many current treatment
regimens for AT/RTs are derived from the strategies for PNET/
MB, which are usually multimodal, and consist of radical surgery,
chemotherapy, and radiotherapy. However, despite aggressive
surgical and adjuvant radiochemotherapy, the outcome of AT/
RT has been uniformly poor [8–10].
Because AT/RT can be difficult to distinguish from PNET/
MB, the differential diagnosis of these tumors is very important
[5,9,11,12]. As the word teratoid indicates, AT/RTs show the
multiple-lineage developmental characteristics of malignant tera-
tomas of neuroectodermal, mesodermal, and endodermal lineages
[6,13,14]. AT/RT expresses a wide range of immunohistochem-
ical markers, such as vimentin, epithelial membrane antigen,
cytokeratin, synaptophysin, glial fibrillary acidic protein, and
smooth muscle actin [6,13,14]. Cytogenetic studies provide a
useful tool in differential diagnosis of brain tumors. Previous
studies have demonstrated 17p loss in 25–50% of medulloblasto-
mas, but not in AT/RT [4–6]. Rorke et al further found that a
subset of AT/RT contain the chromosomal abnormality,
monosomy, or contain a deletion of chromosome 22 [15]. Recent
studies reported that in a CNS rhaboid tumor an unbalanced 9;22
translocation leads to loss of 22q11 [16]. Subsequently, the
hSNF5/INI1 gene on 22q11.2 was identified as a potential tumor
PLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2090suppressor gene responsible for the oncogenesis of AT/RT
[17,18].
Recently, CD133 (prominin-1: PROM1), a 5-transmembrane
glycoprotein, was identified as an important marker representing a
subset population of cancer stem-like cells (CSCs) in leukemia,
retinoblastoma, colon cancer, prostate carcinoma, brain tumor,
and hepatoma [19–23]. Bao et al. further demonstrated that the
fraction of tumor cells expressing CD133, a marker for both neural
stem cells and brain cancer stem cells, is enriched after radiation in
gliomas [24]. Interestingly, these CD133-expressing CSCs play a
critical role not only in the restoration of tumor cells and CSCs but
also in the resistance to radiotherapy [24,25]. In this study, using
magnetic bead selection [19,24], we successfully isolated CD133-
positive cells from tissue samples of AT/RT patients. We found
that CD133-positive AT/RT cells (CD133
+) have a pluripotent
differentiation ability and the capability of malignant cells to be
highly resistant to ionizing radiation (IR). To further characterize
the radioresistant properties and underlying pathogenesis of
CD133
+ cells in AT/RT, CD133
+ and CD133-negative AT/RT
cells (CD133
2) were irradiated with 10 Gy IR and their
genotoxic–response profiles analyzed by cDNA microarray. The
microarray data indicated that CD133
+ display greater checkpoint
activation in response to DNA damage and higher antiapoptotic
activity in radioresistance. Therefore, we further attempted to
investigate the DNA repair and antiapoptotic activity of IR-treated
CD133
+, and to explore the possible mechanisms and therapeutic
rationales associated with these radioresistant responses.
Results
Isolation and Characterization of CD133-positive cells
from AT/RT tissues
A total of nine patients diagnosed with AT/RT are included in
this study. Tumors from these nine patients were all positive for
vimentin, epithelial membrane antigen, cytokeratin, neuron-
specific enolase, glial fibrillary acidic protein, and synatophysin
(Figure 1A and data not shown). Fourteen tumor samples from
these nine patients were analysed by comparative genomic
hybridization (CGH) and molecular analysis for SMARCB1
(hSNF5/INI1). With the use of magnetic beads, CD133-positive
AT/RT cells (CD133
+) were isolated from the 14 tissue samples
from the 9 AT/RT patients (Figure 1B; Table 1). Immunofluo-
rescence confirmed that CD133 was highly expressed in sorted
CD133
+ (green fluorescence; Figure 1C), while there was no
Figure 1. Isolation and Characterization of CD133
+ from AT/RT tissues. (A) Imunohistochemical analysis of tumors from AT/RT patients for
the AT/RT associated markers of vimentin (VIM), epithelial membrane antigen (EMA), cytokeratin (CK), and neuron-specific enolase (NSE). Using a
magnetic bead method, CD133
+ cells were isolated from 9 AT/RT patients, and identified by (B) Flow cytometry, and (C) Immunofluorescence (green
fluorescence: positive for CD133 marker; bar: 20 mm). (D) The result of chromosomal analysis of CD133
+ AT/RT cells analyzed by comparative genomic
hybridisation (CGH). Data shown here are the mean6SD of three experiments.
doi:10.1371/journal.pone.0002090.g001
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2 (Figure 1C). Furthermore, we
analyzed these CD133
+ for chromosomal abnormalities by CGH
and molecular analysis for SMARCB1. The result showed that
these CD133
+ presented with the chromosomal abnormalities
identified in a subset of AT/RT of monosomy, mutation, or
deletion of chromosome 22, which are typical features of AT/RTs
[17,18]. (Figure 1D; Table 1)
Determination of cancer stem-like cell properties in
CD133
+ AT/RT cells
Having isolated the CD133
+ cells from the AT/RT patients, we
next determined their cancer stem-like cell properties. CD133
+
had a higher proliferation rate than CD133
2, as assessed by the
MTT assay (p,0.05, Figure 2A), and were more invasive in in vitro
matrigel Transwell invasion assays when compared to CD133
2
(p,0.05; Figure 2B). When equal numbers of cells were plated in
soft agar, CD133
+ had a higher ability for tumor colony formation
than CD133
2 (p,0.05; Figure 2C). To determine the in vivo
tumorigenic capacity of CD133
+ and CD133
2, increasing
numbers (300, 10
3,3 610
3,1 0
4) of cells were injected into the
brain stratum of SCID mice. The results showed that 10
4 CD133
2
did not induce tumor formation but 3000 CD133
+ from the nine
patients (100%; Table 1) and 300 CD133
+ from one of four
patients (25%; Table 2) generated visible tumors in xenotrans-
planted mice 8 weeks after injection (Figure 2D; Patient No. 2).
Moreover, one thousand CD133
+ isolated from a transplanted
brain tumor can further generate new (2
nd) tumors (data not
shown). To investigate further whether CD133
2 AT/RT can
generate tumors in transplant recipients, higher doses (10
5 and
10
6) of CD133
2 isolated from 4 patients were injected into the
brain striatum of SCID mice. The results showed that tumors can
be detected in the brain lesions after 8 weeks when 10
5 cells (25%;
1 of 4 patients; Patient No. 4) and 10
6 cells (4 of 4 patients; 100%)
of CD133
2 AT/RT were implanted into SCID mice (Figure 2D;
Table 2).
In addition, to investigate the stem-like cell properties of the
CD133
+ and CD133
2 derived from AT/RT, the ability to form
spheroid bodies and the multilineage differentiation ability were
tested. Isolated CD133
+ and CD133
2 AT/RT cells were cultured
in DF-12 serum-free medium with bFGF and EGF (20 ng/mL;
Methods S1). After being in culture for 4 weeks, CD133
+
aggregated and formed spheroid bodies (Figure 3A). The ability
Table 1. Case description and tumorigenic characteristics of CD133
+ AT/RT.
Number of cells injected (cell no.)
Case Age/Sex Molecular Analysis* Survival time CD133
+ (%) CD133
+ CD133
2
1 0.7 / M Positive 0.2 yr 36.4 10,000 (3/3) 10,000(0/3)
3,000(3/3) 3,000(0/3)
1,000(2/3) 1,000(0/3)
2 2.3 / F Positive 0.3 yr 21.8 (69.5)** 10,000 (3/3) 10,000(0/3)
3,000(3/3) 3,000(0/3)
1,000(3/3) 1,000(0/3)
3 2.8 / M Positive 4.4 yr 7.3 (29.6)** 10,000 (3/3) 10,000(0/3)
3,000(3/3) 3,000(0/3)
1,000(3/3) 1,000(0/3)
4 5.1 / M Positive 1.7 yr 25.9 (43.1)** 10,000 (3/3) 10,000(0/3)
3,000(3/3) 3,000(0/3)
1,000(3/3) 1,000(0/3)
5 1.4 / M Positive 8.7 yr 1.3 10,000 (2/3) 10,000(0/3)
3,000(1/3) 3,000(0/3)
1,000(0/3) 1,000(0/3)
6 3.3 / F Positive 7.5 yr 1.6 10,000 (2/3) 10,000(0/3)
3,000(1/3) 3,000(0/3)
1,000(1/3) 1,000(0/3)
7 8.1 / F Positive 4.7 yr 2.4 (37.5)** 10,000 (3/3) 10,000(0/3)
3,000(3/3) 3,000(0/3)
1,000(0/3) 1,000(0/3)
8 5.1 / M Positive 1.7 yr 3.9 (48.5)** 10,000 (3/3) 10,000(0/3)
3,000(3/3) 3,000(0/3)
1,000(3/3) 1,000(0/3)
9 1.7 / M Positive 2.5 yr 10.7 10,000 (3/3) 10,000(0/3)
3,000(3/3) 3,000(0/3)
1,000(2/3) 1,000(0/3)
*molecular analysis includes detection of deletion or mutation of 22q11.2 and hSNF5/INI1 gene and CGH findings.
**the second surgery for tumor relapse. CD133
+ and CD133
2 cells were injected into the stratum of brains of SCID mice.
doi:10.1371/journal.pone.0002090.t001
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+ AT/RT was significantly
higher than that in CD133
2 (p,0.05; Figure 3B). Immunofluo-
rescence staining demonstrated that CD133
+-SB can differentiate
into MAP-2-positive (neuron marker) and GFAP-positive (astro-
glial marker) neuronal-like cells (Figure 3C). Furthermore, ten
thousand cells from CD133
+-SB were injected into the subrenal
space of SCID mice. After 6 weeks, histological analysis indicated
that teratoma-like tissues had formed at the injection site
(Figure 3D). Importantly, we could demonstrate by hematoxylin
and eosin staining development of the three germ layers including
endothelium-like tissues (Figure 3D2), epidermoid tissues
(Figure 3D3), muscle-like tissue (Figure 3D4), cartilage-like tissues
(Figure 3D5), and neuroepithelium-like tissues (Figure 3D6). In
contrast, CD133
2 formed only a few spheres (CD133
2-SB) after 4
weeks in serum-free medium with bFGF and EGF. CD133
2-SB
did not exhibit any multi-lineage differentiation in vitro (Figure 3C)
Figure 2. Cell growth rate, invasive ability, and tumor formation ability of CD133
+/2 AT/RT cells. The growth rate and tumorigenic
ability of CD133
+/2 AT/RT cells were analyzed by using (A) MTT assay, (B) In vitro matrigel Transwell invasion assay, and (C) soft agar formation assay.
*p,0.05 (D) The in vivo tumorigenic activity of CD133
+/2 AT/RT cells was assessed by injecting increasing numbers of cells into the brain stratum of
SCID mice. Tumors develop with as few as 300 CD133
+ AT/RT cells (Patient No. 2), whereas 10
5 CD133
2 (Patient No. 4) are needed to produce
tumors. Bar: 150 m.
doi:10.1371/journal.pone.0002090.g002
Table 2. Investigation of tumorigenicity frequency of CD133
+ and CD133
2 cells derived from four AT/RT patients in NOD/SCID
xenotransplant assay.
Cell Number for Injection
Total of 4 Patients 300 10
3 10
4 10
5 10
6
CD133
+ One of four All positive All positive All positive) All positive
(25%) (100%) (100%) (100%) (100%)
CD133
2 None None None One of four All positive
(0%) (0%) (0%) (25%) (100%)
doi:10.1371/journal.pone.0002090.t002
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Combining these results, our data indicated that CD133-positive
cells isolated from AT/RT tissues present with the characteristics
of cancer stem-like cells.
Measurement of radiosensitivity in C133
+/2 AT/RT in
vitro and in vivo
To determine the effect of radiation on tumor growth rate, an
ionizing radiation (IR) dose from 0 to 10 Gy was used to treat
the two groups of cells. As shown in Figure 4A, the survival rate
and number of CD133
+ after IR treatment were significantly
higher than those of CD133
2 (p,0.05). In order to determine
the effect of radiation on the in vivo proliferation abilities of
CD133 cells, SCID mice were irradiated one week after
CD133
+ and CD133
2 were injected into the brain stratum of
SCID mice for analysis of in vivo tumorigenicity. The total
volumes of CD133
+ tumors in irradiated SCID mice were
significantly higher than those of CD133
2 AT/RT tumors in
mice after IR treatment. Furthermore, there was no significant
difference in the growth of CD133
+ cells in irradiated SCID
mice compared to non-irradiated mice (p.0.05; Data not
shown).
Moreover, expression of CD133
+ in the AT/RT patients
during the course of treatment was investigated using flow
cytometry and immunohistochemistry. As shown in Table 1,
Patient No. 2, 3, 4, 7, and 8 received the complete course of
radiotherapy combined with chemotherapy. However, the tumor
relapsed and these five patients then underwent a second brain
s u r g e r y .T h ep e r c e n t a g eo fC D 1 3 3
+ (Figure 4B&C) was
dramatically elevated in the tumor relapse samples of these five
patients as compared to the tumor samples from their first
surgery (Figure 4D; Table 1). In addition, treatment efficacy and
mean survival time of these 9 AT/RT patients significantly and
negatively correlated with the levels of CD133
+ cells in the
patients’ tissues (p,0.05; Table 1). Taken together, these data
supported the claim that the amount of CD133
+ cells in AT/
RTs is strongly and positively correlated with the level of
resistance to radio/chemotherapy as well as the occurrence of
tumor relapse.
Figure 3. Multi-lineage differentiation capability of CD133
+/2 AT/RT cells. (A) and (B) sphere formation of CD133
+/2 AT/RT cells. CD133
cells were cultured in serum free medium with bFGF and EGF (20 ng/mL) for 4 weeks. (C) CD133
+ AT/RT cells were cultured for 14 days on a poly-L-
lysine coated plate in medium containing 2% FBS. The percentages of MAP-2-positive (MAP-2: neuron marker) and GFAP-positive cells (GFAP: glia
marker) were detected in the differentiated CD133
+ AT/RT cells. DAPI: staining for cell nuclei (blue fluorescent; bar: 20 mm).*p,0.05. (D) CD133
+ AT/
RT cells were injected into the subrenal space of a SCID mouse (n=6). All the mice formed teratomas. (1) arrow: normal kidney tissue of the mouse.
The three germ layers include (2) endothelium-like tissues (arrow), (3) epidermoid tissues (arrow), (4) muscle-like tissue (arrow), (5) cartilage-like
tissues (arrow), and (6) neuroepithelium-like tissues (arrow); bar: 100 mm. Data shown here are the mean6SD of three experiments.
doi:10.1371/journal.pone.0002090.g003
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repair gene clusters in CD133
+/2 AT/RT cells after
ionizing radiation
Microarray analysis showed that the expression of 1494 genes
(Figure S1A–C) were significantly altered in IR-treated CD133
+
as compared to IR-treated CD133
2 at 0.5, 2, 6, 12 and 24 h
post-IR when compiled with the hierarchical clustering method
(Figure 5A). The time-dependent expression profiles of the 1494
genes were further analyzed by using GeneSpring software
(Figure 5; Figure S1). A total of 327 genes (Figure 5B) differed
significantly in their expression levels between IR-treated
CD133
+ a n dI R - t r e a t e dC D 1 3 3
2 by more than two-fold (up-
regulation) or less than 0.5-fold (down-regulation) (p,0.05).
They can be divided into three major groups: (1) anti-apoptotic
and apoptotic genes, (2) cell cycle-related genes, and (3) DNA
repair-related genes, as visualized and analyzed by GenSpring
GX Gene Tree Clustering (Figure 5C). Using real-time RT-PCR
toconfirm themicroarray data, weshowed thatBCL-2and BCL-
XL were significantly u p - r e g u l a t e da t0 . 5 ,2 ,6 ,1 2a n d2 4hi n
irradiated CD133
+ as compared to IR-treated CD133
2
(Figure 2S). The expression level of CDKN1A (p21
Waf1/Cip1)
was up-regulated in CD133
+ at 0.5 and 2 h post-IR, but showed
significant down-regulationa t6 ,1 2a n d2 4 hp o s t - I Ra s
compared to IR-treated CD133
2 (Figure 2S). Moreover, the
expression levels of TP53BP1 in CD133
+ cells gradually
increased from 2 h to 24 h post-IRa sc o m p a r e dt oI R - t r e a t e d
CD133
2 cells (Figure 2S). In addition, the results of Western blot
analysis were consistent with the gene expression profiles of BCL-
2, BCL-XL, CDKN1A, and TP53BP1 in CD133
+ cells after IR
(Data not shown). Thus, the differential expression of genes
associated with cell-cycle, growth, transcription signaling, anti-
apoptosis, and apoptosis (Figure 5C and Figure 2S) could initiate
signaling cascades leading to and/or preparing for the subse-
quent events of cell-cycle arrest, inhibition of proliferation and
DNA repair, which could eventually lead to cell repair, regrowth,
and mutagenesis in IR-treated CD133
+ cells. In addition, we
used a literature-based network analysis of all MEDLINE records
(title and abstract) to group the target-linkage genes from our
microarray data using a Natural Language Processing (NLP)
regimen for gene and protein names. We identified thirty-seven
literature-based network genes that were involved and altered
after IR (Figure 5D and Table S1). Of these 37 genes, 19 genes
(Table S1) are in rosy symbols and the co-expressed genes (sorted
by PubGene) are in crimson. The results of this literature linkage
Figure 4. Evaluation of radiosensitivity in C133
+/2 AT/RT cells in vitro and in vivo. (A) The survival fraction of CD133
+/2 AT/RT cells after IR
treatment. The IR dose: from 0 to 10 Gy. (B) Detection by immunohistochemistry of CD133
+ AT/RT cells in the tissue samples of the same patient after
the first surgery and the second surgery (tumor recurrence) (bar: 50 mm). (C) The percentage of CD133
+ AT/RT cells (1
st surgery: 9 patients) was
dramatically elevated in the tumor relapse samples (2
nd surgery: 5 patients). (D) Comparison of the tumor samples from the first and second surgeries
in the five patients whose tumors relapsed. *p,0.05; **p,0.001. Data shown here are the mean6SD of three experiments.
doi:10.1371/journal.pone.0002090.g004
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expression is involved in the activation of anti-apoptosis, cell
cycle, and DNA repair related gene clusters.
Increased phosphorylation of ATM-related proteins and
expression of BCL-2 protein in CD133
+ AT/RT cells in vitro
and in vivo after IR
To further validate DNA damage checkpoint responses in
CD133
+ radioresistant AT/RT cells, we compared early ATM-
related DNA damage responses in CD133
+ and CD133
2
subpopulations of AT/RT cells. Consistent with our microarray
findings, the activating phosphorylation of the checkpoint
proteins, p-ATM, p-RAD17, and p-CHK2, was significantly
higher in IR-treated CD133
+ than in IR-treated CD133
2
(Figure 6A), indicating that CD133
+ AT/RT cells display greater
checkpoint activation in response to DNA damage. Immunoflu-
orescence analysis confirmed that the expression of BCL-2 in IR-
treated CD133
+ was significantly higher than that in IR-treated
CD133
2 (p,0.05; Figure 6B). Interestingly, it was also noted that
higher endogenous levels of BCL-2 protein and of phosphorylated
ATM, RAD17 and CHK2 were detected in CD133
+ without any
treatment (Figures 6A & 6B). Moreover, we investigated whether
the up-regulated expression of BCL-2 can increase the IR-
resistant and anti-apoptotic activities in IR-treated CD133.
Irradiated CD133 cells were treated with cisplatin (1 mg/ml) or
TRAIL (100 ng/ml) alone, or in combination. As shown in Figure
S3A, the cell survival rate in IR-treated CD133
+ was not
significantly decreased by the IR treatment combined with
cisplatin, with or without TRAIL treatment. In contrast, cell
Figure 5. The alteration of anti-apoptosis, cell cycle, and DNA repair gene clusters in CD133
+/2 AT/RT cells after ionizing radiation
(IR). (A) Gene tree for the experiments at 5 time points (0.5, 2, 6, 12 and 24 h post-IR) of the 1494 altered genes in IR-treated CD133
+ AT/RT cells as
compared to IR-treated CD133
2 cells. The time dependent changes of 1494 altered genes are presented as a log scale of the expression values
provided by GeneSpring GX software. (B) Molecular functions of the 327 significant genes (.two-fold up-regulation and ,0.5-fold down-regulation)
expressed in irradiated CD133
+/2 AT/RT cells. (C) There are three major gene groups were identified by GenSpring GX Gene Tree Clustering: anti-
apoptosis and apoptosis, Cell Cycle, and DNA Repair. The correlations are indicated to the left of the corresponding nodes. Selected lots of functional
genes are indicated to the right. The values given are the linear ratio of the average from three replicate experiments. (D) Thirty-seven literature-
based network genes were involved and altered after IR. Of these 37 genes, 19 genes (Table S1) based on the results of our study were in rosy
symbols and the co-expressed genes (sorted by PubGene) were in crimson. The expression presence of CD133 was directly correlated with BCL2,
BCL2L1, BAX, TNF, MK167, IL2RA, TP53, and MDM2. Lines indicate co-citation in the literature in more than one article. The numbers indicate the
number of Medline records containing the query term or one of its synonyms at least once. This tool allows us to explore in detail the literature
associations between a set of genes, proteins or the combination of the two. The literature networks are based on the results of indexing using a
Natural Language Processing (NLP) regimen of all MEDLINE records (title and abstract) for gene and protein names.
doi:10.1371/journal.pone.0002090.g005
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2 declined significantly after treatment with
cisplatin alone and in combination with TRAIL (Figure S3A). IR
with cisplatin or TRAIL alone, or in combination, increased
caspase 3 activity in CD133
2, however, there was no significant
difference in caspase 3 activity in similarly treated CD133
+
(Figure S3B).
In order to further confirm whether the in vivo expression of
phosphorylated ATM and BCL-2 protein in transplanted mice
was also influenced by IR treatment, SCID mice transplanted
with CD133
+ or CD133
2 received irradiation with or without
cisplastin. Immunohistochemical analysis (Figure 6C) demon-
strated that both p-ATM (Figure 6D) and BCL-2 protein
(Figure 6E) were up-regulated more in IR-treated CD133
+ than
in IR-treated CD133
2. Secondly, using an in vivo GFP imaging
system to visualize the tumor [26], the tumor volume of CD133
+
cannot be effectively diminished by IR treatment alone, cisplatin
alone, or a combination of IR/cisplatin as compared to the same
treatment of CD133
2 (Figure S3C). Finally, Kaplan-Meier
survival analysis indicated that the mean survival rate of mice
with IR/cisplatin-treated CD133
+ was significantly lower than
those with CD133
2 or IR/cisplatin-treated CD133
2 (Data not
shown).
Enhanced radiosensitivity of CD133
+ AT/RT cells after
combined treatment with a checkpoint kinases inhibitor
and BCL-2 siRNA
To further investigate the role of the increased phosphorylation
of ATM-pathway proteins and expression of BCL-2 protein in
CD133
+ AT/RT, we treated the cells with debromohymenialdi-
sine (DBH; an inhibitor of checkpoint kinases, 3 mM; Calbio-
chem, USA) alone or in combination with silencing of the BCL-2
gene [27] with small interfering RNA (siRNA) with a lentiviral
vector (Figure 7A; Methods S1). The result showed that the effect
of IR on CD133
+ can be significantly improved by DBH alone or
DBH in combination with BCL-2 siRNA (Figure 7A). Compared
with IR-treated only CD133
+, the tumorigenic properties of
migration/invasion (Figure 7B) and tumor colony formation
(Figure 7C) were significantly inhibited in CD133
+ treated with
DBH alone or DBH combined with BCL-2 siRNA. These data
indicated that the radioresistance of CD133
+ to IR is partially due
to preferential activation of checkpoint kinases and Bcl-2 proteins.
In order to further confirm the proliferative and IR-resistant
abilities of CD133
+ AT/RT in vivo, the eight groups - CD133
+,
CD133
2, only IR-treated CD133
+, only IR-treated CD133
2,
DBH-treated CD133
+, DBH/IR-treated CD133
+, DBH/BCL-2
Figure 6. Detection of phosphorylated ATM-related proteins and of BCL-2 protein in CD133
+/2 AT/RT after IR. (A) Using Western
blotting analysis, increased levels of phosphorylation of p-ATM, p-RAD17, and p-CHK2 were detected in IR-treated CD133
+ AT/RT cells compared to
IR-treated CD133
2 AT/RT cells. (B) Immunofluorescent staining of BCL-2 protein in CD133
+/2 AT/RT cells before and after IR. Bar: 100 mm. (C) To
further study protein expression in CD133
+/2 AT/RT xenotransplanted grafts in SCID mice with or without IR, tumor growth in the brain of SCID mice
was evaluated by in vivo GFP imaging and immunohistochemistry (IHC). The expression of (D) p-ATM protein and (E) BCL-2 protein in the brain
lesions of CD133
+/2 AT/RT -injected mice were detected by IHC. Bar: 150 mm. *p,0.05. Data shown are the mean6SD of three experiments.
doi:10.1371/journal.pone.0002090.g006
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+, and DBH/BCL-2 siRNA/IR-treated
CD133
+ were individually injected into the tail vein of SCID mice
for xenotransplanted tumorigenicity analysis. The tumor foci and
volumes of CD133
+ treated by DBH+IR alone or DBH+IR
combined with BCL-2 siRNA were significantly decreased
compared to those of CD133
+ and only IR-treated CD133
+
(p,0.01; Fig. 8A). Importantly, Kaplan-Meier survival analysis
further indicated that the mean survival rates in CD133
+ treated by
DBH+IR alone or DBH+IR combined with BCL-2 siRNA can be
significantly prolonged compared to CD133
+ and only IR-treated
CD133
+ (p,0.01; Fig. 8B). Moreover, in vivo study also confirmed
that the effectiveness of chemotherapy for CD133
+ cells can be also
improved by the treatment with DBH in combination with BCL-2
siRNA (data not shown). These data provide evidence that targeting
the p-ATM pathway and BCL-2 in CD133
+ cells will be vital for
improving the treatment of deadly diseases like AT/RT.
Discussion
Radiotherapy and chemotherapy play significant and crucial
roles in prolonging cancer patient survival, and a recent study
showed that radiotherapy is promising and might be more
efficacious than chemotherapy for AT/RT patients [8–10].
However, there is still a high failure rate and low median survival
in AT/RTs undergoing radiotherapy when compared to patients
with other pediatric CNS tumors, like medulloblastoma [9,10].
In this study, we isolated CD133
+ cells from nine AT/RT
patients (Figure 1) and found that the percentage of CD133
+
strongly and negatively correlated with the clinical outcome
(mean survival time and treatment efficacy) of AT/RT patients
(Table 1). In five AT/RT patients whose tumors relapsed after
radiochemotherapy, the percentage of CD133
+ in the relapsed
tumor was significantly higher than in the original tumor
(Figure 4; Table 1). We also found that CD133
+ isolated from
the nine AT/RT patients expressed severe deletion of chromo-
some 22q11 (Figure 1; Table 1), and these cells further
demonstrated a self-renewal capability, rapid growth rate, and
multipotential to differentiate into three germ layers (Figures 2 &
3). The migration, invasion, malignancy, and radioresistant
capabilities, shown by in vitro and in vivo assays, of CD133
+ cells
were also significantly higher than those of the parental CD133
2
cells (Figures 2 & 4). CD133
+ AT/RT cells preferentially activate
Figure 7. Enhanced radiosensitivity of CD133
+ AT/RT cells after combined treatment with a checkpoint kinases inhibitor and BCL-2
siRNA. (A) Western blott data showed that the protein levels of BCL-2 in CD133
+ AT/RT were significantly upregulated compared with those of
CD133
2. Treatment of BCL-2 siRNA can efficiently block the protein expression of BCL-2 in CD133
+ (upper part). The effect of IR on CD133
+ AT/RT cells
was significantly improved by DBH alone or DBH in comination with BCL-2 siRNA (lower part). The tumorigenic properties of (B) migration/invasion
and (C) tumor colony formation were significantly inhibited in CD1332 AT/RT cells treated by DBH alone or DBH combined with BCL-2 siRNA as
compared to CD133
+ and IR-treated only CD133
+ groups. *p,0.05. Data shown are the mean6SD of three experiments.
doi:10.1371/journal.pone.0002090.g007
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antiapoptotic (BCL-2 and BCL-XL) genes in response to IR
(Figure 5; Figure S1 & Figure S2). Furthermore, they repair
radiation-induced DNA damage and anti-apoptotic activity
more effectively than CD133
2 AT/RT cells. The results of in
vivo GFP imaging and immunohistochemical analyses confirmed
that the up-regulated expression of p-ATM and BCL-2 proteins
positively correlated with the failure rates of radiochemotherapy,
a n dn e g a t i v e l yc o r r e l a t e dw i t h the mean survival times of IR-
treated CD133
+ xenotransplanted mice as compared to the
CD133
2 transplanted mice (Figure 6; Figure S3). Importantly,
the radiation- and/or chemodrug- resistance of CD133
+ AT/RT
invitroand in vivocouldbesignificantlyreversedby treatmentwith
DBH (a specific inhibitor of CHK1 and CHK2) combined with
BCL-2 siRNA (Figure 7). In addition, Kaplan-Meier survival
analysis further indicated that the mean survival rate of mice with
CD133
+ under radiation treatment could be significantly
improved when combined with DBH alone or DBH together
with BCL-2 siRNA (Figure 8). To our knowledge, this is the first
study to report the presence of CD133
+ in AT/RT, and to show
that the activated p-ATM pathway and BCL-2-related anti-
apoptotic activity in CD133
+ and IR-CD133
+ render the
CD133
+ subpopulation capable of causing radio/chemoresis-
tance in malignant tumors.
CD133 has been considered an important marker of a subset of
CSCs in brain tumors [19–22]. A recent report suggested that
expression of CD133 antigen in glioma could serve as a prognostic
indicator for tumor regrowth, malignant progression, and patient
survival [28]. In our study investigating the role of CD133
+ in the
tumorigenicity of AT/RT, we found that as few as 300 CD133
+
AT/RT cells could induce tumor formation in xenotransplanted
mice (Table 2; Figure 2D). Our data indicated that CD133
+
contain the self-renewing and repopulation capabilities in vitro and
in vivo that CD133
2 AT/RTs lack unless a high cell number (10
5
to 10
6) was used as an inoculum in SCID mice (Figure 2, Table 2).
Similar to our finding, Beier et al. has suggested that CD133
2
glioblastoma cells possess a small subpopulation of cancer stem
cells which have the ability to drive tumor growth in vivo [29].
Thus, whether CD133 is indeed the novel surface marker which
allows the separation of cancer stem cells or tumor-initiating cells
from brain tumors needs further investigation.
Several genes known to be involved in DNA damage repair
(double strand-break rejoining), such as the ATM, GADD45,
Ku80 (XRCC5), and ERCC5, showed increased expression in
CD133
+ AT/RT cells post IR treatment (Figure 5). ATM, a
protein defective in the heritable disorder, ataxia telangiectasia, is
a central signaling kinase in the response to double strand breaks
and is involved in the regulation of cell cycle checkpoints [30–32].
Figure 8. Significantly improved tumor growth and prolonged survival rate in CD133
+ AT/RT cells transplanted SCID mice by the
combined treatment of a checkpoint kinases inhibitor and BCL-2 siRNA. (A) The tumorigenicity analysis showed that the number of tumor
foci and tumor volumes in tumor-bearing SCID mice treated by DBH+IR alone or DBH+IR combined with BCL-2 siRNA were significantly lower than
those of CD133
+ or only IR-treated CD133
+. Moreover, the effectiveness of radiotherapy for CD133
+ cells can be also improved by the treatment with
DBH in combination with BCL-2 siRNA (*p,0.05: CD133
+/DBH Vs. CD133
+/DBH/IR; CD133
+/DBH/BCL-2 siRNA Vs. CD133
+/DBH/BCL-2 siRNA/IR). (B)
Kaplan-Meier survival analysis further indicated that the mean survival rates in CD133
+ treated by DBH+IR alone or DBH+IR combined with BCL-2
siRNA group can be significantly prolonged compared to CD133
+ and only IR-treated CD133
+ groups. Data shown are the mean6SD of three
experiments.
doi:10.1371/journal.pone.0002090.g008
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+ glioma
cells can activate ATM-related DNA damage checkpoint respons-
es. They suggested that the radioresistance of CD133
+ cells is
triggered by preferential checkpoint activation [24]. In agreement
with their findings, our results revealed activated and phosphor-
ylated ATM and its downstream effectors (Figures 5, 6; Figure S2),
CHEK1, CHEK2, MDC1, RAD17, RAD23A, RAD52, CDK2,
CDC25, and TP53BP1, which were also up-regulated in CD133
+
AT/RT cells in response to IR. Importantly, Mirzayans et al.
reported that ATM-deficient cells exhibited marked radiosensitiv-
ity and p53-deficient cells had varying degrees of radioresistance
compared with normal fibroblasts [33]. The expression of tumor
protein p53 (TP53) in CD133
+ AT/RT cells was first up-regulated
2 hours after IR but was then significantly inhibited 4 hours after
IR (Figure 5; Figure S2). Cyclin-dependent kinase inhibitor 1A
(p21, Cip1), the downstream protein of TP53 [34–36], presented a
similar pattern in irradiated CD133
+ AT/RT cells (Figure 5;
Figure S2). Interestingly, we found that the levels of MDM2, a
nuclear phosphoprotein which binds to TP53 [37], were
significantly up-regulated in CD133
+ AT/RT cells 4 hours after
IR (Figure 5; Figure S2). Indeed, over-expression of MDM2 can
result in excessive inactivation of TP53, diminishing its tumor
suppressor function [37,38].
Expression of the apoptosis gene BAX was slightly increased in
CD133
+ AT/RT cells 2 hours after IR and significantly
suppressed 4 hours after IR (Figure 5; Figure S2). In contrast,
expression of the anti-apoptotic genes BCL-2 and BCL-XL was
significantly and rapidly (2 h) up-regulated in CD133
+ AT/RT
cells and remained elevated 24 hours post IR (Figure 5; Figure S2).
Over-expression of BCL-2 in malignant laryngeal cancer is
considered a contributing factor to radiotherapy failure [39].
The induction of a radioadaptive response in human lymphoblas-
toid cells can be abrogated by either loss of TP53 or BCL-2 over-
expression [40]. Recently, increased phosphorylation of ATM
(ATMpSer1981) and CHK2 (CHK2pTHr68) was specifically
found in the precursors of prostatic carcinoma [41]. Consistent
with these findings, over-expressed p-ATM and BCL-2 proteins
positively and significantly correlated with radioresistant responses
and high mortality rates in vitro and in vivo in our IR-treated
CD133
+ (Figure 6; Figure S3). According to the functional-linkage
analysis of literature-based network from the microarray data,
CD133 (PROM1) plays a role in maintaining a relationship
between BCL-2, BAX, CHEK2, MDM2, ATM, TP53, ATR,
CDK2, CDC25C, TP53BP1 (Figure 5D and Table S1). Thus, our
results imply that CD133
+ AT/RT cells represent the cellular
population which confers AT/RT radioresistance, and could be
the source of tumor recurrence after radiation.
In conclusion, our data indicate that CD133
+ AT/RTs present
both the characteristics of stem cells and malignant tumors. The
radio/chemoresistant and anti-apoptotic properties in CD133
+
AT/RT cells may reflect the clinical refractory malignancy of AT/
RTs as well as cancer stem-like cells. This CSCs property in AT/
RT and other tumors should be considered in future translational
oncology as instrumental to ultimately improving anti-cancer
therapies. In addition, the activated p-ATM-related DNA repair
pathway and anti-apoptotic genes in the CD133
+ subset could be
warranted as possible targets to improve the therapy for the
treatment of advanced malignant brain tumors.
Materials and Methods
Isolation of CD133
+ cell subsets from AT/RT tissues
This research followed the tenets of the Declaration of Helsinki
and all samples were obtained after patients had given their
informed consent. The dissociated cells from the samples of brain
tumors from AT/RT patients were labeled with 1 mL CD133/l
micromagnetic beads per 1 million cells using the CD133 cell
isolation kit (MACS, Miltenyi Biotec). CD133
+ cells were cultured
in serum-free DMEM/F12 (GIBCO) medium, supplemented with
N2 supplement (R&D), 10 ng/mL human recombinant bFGF
(R&D) and 10 ng/mL EGF [42]. The Gamma Radiation was
delivered by Theratronic cobalt unit T-1000 (Theratronic
Internation, Inc., Ottawa, Canada) at a dose rate of 1.1 Gy/min
(SSD=57.5 cm). For the evaluation of cell proliferation rate, cells
were seeded on 24-well plates at a density of 2610
4 cells/well in
medium, followed by the methyl thiazol tetrazolium assay (MTT
assay; Sigma-Aldrich Co.). The amount of MTT formazan
product was determined using a microplate reader and an
absorbance of 560 nm (SpectraMax 250, Molecular Devices,
Sunnyvale, CA, USA).
Comparative genomic hybridisation (CGH)
The CGH procedure was described in a previous publication
[43], namely, metaphase spreads from the patient lymphocytes
were prepared using standard protocols. Nick-translated, spectrum
red-labeled tumor DNA and spectrum green-labeled normal DNA
were coprecipitated with excess unlabeled human Cot-1 DNA
(GibcoBRL), denatured, and hybridized to the normal metaphase
slide preparations. Ten to twelve images were captured and
analysed using a Cytovision workstation. The threshold indicated
that gain and loss were set at 1.2 and 0.8, respectively.
Microarray analysis and real-time RT-PCR
Total RNA was extracted from CD133
+ and CD133
2 AT/RT
cells using Trizol reagent (Life Technologies, Bethesda, MD, USA)
and the Qiagen RNAeasy (Qiagen, Valencia, CA, USA) column for
purification. Total RNA was reverse-transcribed with Superscript II
Rnase H-reverse transcriptase (Gibco BRL) to generate Cy3-and
Cy5-labeled (Amersham Biosciences Co., Piscataway, NJ, USA)
cDNA probes for control and treated samples, respectively. The
labeled probes were hybridized to a cDNA microarray containing
10,000gene clone immobilized cDNA fragments[43]. Fluorescence
intensities of Cy3 and Cy5 targets were measured and scanned
separately using GenePix 4000B Array Scanner (Axon Instruments,
Burlingame, CA, USA). Data analysis was performed using
GenePix Pro 3.0.5.56 (Axon Instruments, USA) and GeneSpring
GX 7.3.1 software (Agilent, Palo Alto, CA). The method of real-
time RT-PCR was performed as described [44]. Briefly, total RNA
(1 mg) of each sample was reversely transcribed in 20 mL using
0.5 mg of oligo dT and 200 U Superscript II RT (Invitrogen,
Carlsbad, CA). The primer sequences used in real-time RT-PCR
are shown in Table S2. The amplification was carried out in a total
volume of 20 ml containing 0.5 mM of each primer, 4 mM MgCl2,
2 ml LightCycler
TM–FastStart DNA Master SYBR green I (Roche
Molecular Systems, Alameda, CA) and 2 ml of 1:10 diluted cDNA.
PCR reactions were prepared in duplicate and heated to 95uC for
10 minutes followed by 40 cycles of denaturation at 95uC for
10 seconds, annealing at 55uC for 5 seconds, and extension at 72uC
for 20 seconds. Standard curves (cycle threshold values versus
template concentration) were prepared for each target gene and for
the endogenous reference (GAPDH) in each sample. The
quantification of the unknown samples was performed by the
LightCycler Relative Quantification Software version 3.3 (Roche
Molecular Systems, Alameda, CA).
In vitro cell invasion analysis and soft agar assay
The 24-well plate TranswellH system with a polycarbonate filter
membrane of 8-mm pore size (Corning, United Kingdom) was
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of the Transwell chamber at the cell density of 1610
5 in 100 ml
serum free medium. After 24 hours, the medium was removed and
the filter membrane was fixed with 4% formalin for 1 hour. The
opposite surface of the filter membrane which faced the lower
chamber was stained with Hoechst 33342 for 3 mins and the
migrated cells were then visualized under an inverted microscope.
The protocol of soft agar assay was performed as follows. Each
well (35 mm) of a six-well culture dish was coated with 2 ml
bottom agar mixture (DMEM, 10% (v/v) FCS, 0.6% (w/v) agar).
After the bottom layer had solidified, 2 ml top agar-medium
mixture (DMEM, 10% (v/v) FCS, 0.3% (w/v) agar) containing
2610
4 cells was added, and the dishes were incubated at 37uC for
4 weeks. The plates were stained with 0.5 ml of 0.005% Crystal
Violet for 1 hour, then the number of colonies was counted by a
dissecting microscope [44].
Immunofluorescence staining and
immunohistochemistry
The protocol followed is the one described in the previous study
[45]. Briefly, an avidin-biotin complex method was used for the
immunofluorescence staining in the differentiated spheroid and
neuronal-like cells. Each slide was treated with antibodies for
CD133 (MACS, Miltenyi Biotec), GFAP (Chemicon), and MAP2
(Chemicon), phospho-ATM (Ser-1981; Upstate, Lake Placid, NY)
and BCL-2 (Chemicon). Immunoreactive signals were detected
with a mixture of biotinylated rabbit antimouse IgG and Fluoesave
(Calbiochem, La Jolla).
In vivo analysis of tumor growth and metastasis
All procedures involving animals were in accordance with the
institutional animal welfare guideline of Taipei Veterans General
Hospital. 2610
4 cells CD133
+ and CD133
2 AT/RT cells were
injected into the brain stratum of SCID mice (BALB/c strain) each
aged 8 weeks. In vivo GFP imaging was visualized and measured by
an illuminating device (LT-9500 Illumatool TLS equipped with
excitation illuminating source (470 nm) and filter plate (515 nm)).
The tumor size was measured by a caliper and the volume was
calculated according to the formula: (Length6Width
2)/2. The
integrated optical density of green fluorescence intensity was
captured and then analyzed by Image Pro-plus software [26].
Statistical analysis
The results are reported as mean6SD. Statistical analysis was
performed using Student’s-t test or the one-way or two-way
ANOVA test followed by Turkey’s test, as appropriate. A p,0.05
was considered to be statistically significant.
Supporting Information
Figure S1 The time-dependent expression profiles of the 1494
genes were further analyzed by GeneSpring software. (A–C)
Molecular functions of the 1494 genes expressed in irradiated
CD133+/2 AT/RT cells.
Found at: doi:10.1371/journal.pone.0002090.s001 (0.23 MB TIF)
Figure S2 Detection of mRNA expression levels in CD133+/2
AT/RT cells before and after IR. The expression levels of BCL-2,
BCL-XL, BAX, CDKN1A, TP53BP1, and MDM2 in CD133+
AT/RT cells as compared to CD1332 AT/RT cells by real-time
RT-PCR at 0.5, 2, 6, 12 and 24 h post-IR. Data shown here are
the mean +/2 SD of three experiments.
Found at: doi:10.1371/journal.pone.0002090.s002 (2.61 MB
DOC)
Figure S3 Investigation of the sensitivity to radiochemotherapy
and the antiapoptotic ability of CD133+/2 AT/RT cells. (A) The
cell survival rate in IR-treated CD133+/2 AT/RT cells before
and after treatment with cisplatin (1 ug/ml), TRAIL (100 ng/ml)
or a combination of cisplatin and TRAIL. (B) Caspase 3 activity
was detected by ELISA in IR-treated CD133+/2 AT/RT cells
before and after treatment with cisplatin, TRAIL or a combina-
tion of cisplatin and TRAIL. *p,0.001. Data shown are the mean
+/2 SD of three experiments. (C) The tumor volume in CD133+/
2 AT/RT transplanted SCID mice treated with IR alone,
cisplatin alone, and IR+cisplatin, as measured by GFP imaging
and histology. Data shown are the mean +/2 SD of three
experiments.
Found at: doi:10.1371/journal.pone.0002090.s003 (2.79 MB
DOC)
Methods S1
Found at: doi:10.1371/journal.pone.0002090.s004 (0.10 MB
DOC)
Table S1
Found at: doi:10.1371/journal.pone.0002090.s005 (0.06 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0002090.s006 (0.04 MB
DOC)
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